APO RESEARCH · REPORT
Mesalamine
Mesalamine, also known as Mesalamine, or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.
Product & engineering
Understand the product.
Mesalamine, also known as Mesalamine, or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.
Selected research
Industry Research
Mesalamine Industry Research Report 2026
Market perspective
Mesalamine, also known as Mesalamine, or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.
The industry's leading manufacturers are Syntese A/S, Divis Laboratories, ipca Laboratories and Cambrex Corporation, which accounted for 23.74%, 14.71%, 6.44% and 6.35% of the global revenue share in 2019, respectively.
In terms of regions, the revenue share of Europe is the highest, reaching 41.11% in 2019.
Read the full market overview
Report Scope
This report quantifies the global Mesalamine market in terms of revenue (US$ million) and, where applicable, sales volume (MT), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/MT) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mesalamine Market by Company
Syntese A/S
Divis Laboratories
Cambrex Corporation
Ipca Laboratories
Hangzhou Brother
PharmaZell
Lianyungang Fengheng Biopharm
Lasa Loboratory
Erregierre SpA
Corden Pharma Bergamo
CTX Lifescience
Ishita Active Pharma Ingredients
YC Biotech (Jiangsu)
Xinxiang Tianfeng Fine Chemical
Mesalamine Segment by Type
Purity ≥ 97%
Purity ≥ 98%
Purity ≥ 99%
Mesalamine Segment by Application
Mesalazine Tablets
Mesalazine Capsules
Others
Mesalamine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesalamine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesalamine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesalamine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mesalamine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mesalamine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mesalamine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity ≥ 97%
- Purity ≥ 98%
- Purity ≥ 99%
Applications
- Mesalazine Tablets
- Mesalazine Capsules
- Others
Companies covered
- Syntese A/S
- Divis Laboratories
- Cambrex Corporation
- Ipca Laboratories
- Hangzhou Brother
- PharmaZell
- Lianyungang Fengheng Biopharm
- Lasa Loboratory
- Erregierre SpA
- Corden Pharma Bergamo
- CTX Lifescience
- Ishita Active Pharma Ingredients
- YC Biotech (Jiangsu)
- Xinxiang Tianfeng Fine Chemical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mesalamine Market Size (2021-2032)
- 2.2.2 Global Mesalamine Sales (2021-2032)
- 2.2.3 Global Mesalamine Market Average Price (2021-2032)
- 2.3 Mesalamine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Purity ≥ 97%
- 2.3.3 Purity ≥ 98%
- 2.3.4 Purity ≥ 99%
- 2.4 Mesalamine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Mesalazine Tablets
- 2.4.3 Mesalazine Capsules
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mesalamine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mesalamine Sales (MT) of Manufacturers (2021-2026)
- 3.3 Global Mesalamine Revenue of Manufacturers (2021-2026)
- 3.4 Global Mesalamine Average Price by Manufacturers (2021-2026)
- 3.5 Global Mesalamine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mesalamine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mesalamine, Product Type & Application
- 3.8 Global Manufacturers of Mesalamine, Established Date
- 3.9 Global Mesalamine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Syntese A/S
- 4.1.1 Syntese A/S Company Information
- 4.1.2 Syntese A/S Business Overview
- 4.1.3 Syntese A/S Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Syntese A/S Mesalamine Product Portfolio
- 4.1.5 Syntese A/S Recent Developments
- 4.2 Divis Laboratories
- 4.2.1 Divis Laboratories Company Information
- 4.2.2 Divis Laboratories Business Overview
- 4.2.3 Divis Laboratories Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Divis Laboratories Mesalamine Product Portfolio
- 4.2.5 Divis Laboratories Recent Developments
- 4.3 Cambrex Corporation
- 4.3.1 Cambrex Corporation Company Information
- 4.3.2 Cambrex Corporation Business Overview
- 4.3.3 Cambrex Corporation Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Cambrex Corporation Mesalamine Product Portfolio
- 4.3.5 Cambrex Corporation Recent Developments
- 4.4 Ipca Laboratories
- 4.4.1 Ipca Laboratories Company Information
- 4.4.2 Ipca Laboratories Business Overview
- 4.4.3 Ipca Laboratories Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Ipca Laboratories Mesalamine Product Portfolio
- 4.4.5 Ipca Laboratories Recent Developments
- 4.5 Hangzhou Brother
- 4.5.1 Hangzhou Brother Company Information
- 4.5.2 Hangzhou Brother Business Overview
- 4.5.3 Hangzhou Brother Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hangzhou Brother Mesalamine Product Portfolio
- 4.5.5 Hangzhou Brother Recent Developments
- 4.6 PharmaZell
- 4.6.1 PharmaZell Company Information
- 4.6.2 PharmaZell Business Overview
- 4.6.3 PharmaZell Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 PharmaZell Mesalamine Product Portfolio
- 4.6.5 PharmaZell Recent Developments
- 4.7 Lianyungang Fengheng Biopharm
- 4.7.1 Lianyungang Fengheng Biopharm Company Information
- 4.7.2 Lianyungang Fengheng Biopharm Business Overview
- 4.7.3 Lianyungang Fengheng Biopharm Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Lianyungang Fengheng Biopharm Mesalamine Product Portfolio
- 4.7.5 Lianyungang Fengheng Biopharm Recent Developments
- 4.8 Lasa Loboratory
- 4.8.1 Lasa Loboratory Company Information
- 4.8.2 Lasa Loboratory Business Overview
- 4.8.3 Lasa Loboratory Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lasa Loboratory Mesalamine Product Portfolio
- 4.8.5 Lasa Loboratory Recent Developments
- 4.9 Erregierre SpA
- 4.9.1 Erregierre SpA Company Information
- 4.9.2 Erregierre SpA Business Overview
- 4.9.3 Erregierre SpA Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Erregierre SpA Mesalamine Product Portfolio
- 4.9.5 Erregierre SpA Recent Developments
- 4.10 Corden Pharma Bergamo
- 4.10.1 Corden Pharma Bergamo Company Information
- 4.10.2 Corden Pharma Bergamo Business Overview
- 4.10.3 Corden Pharma Bergamo Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Corden Pharma Bergamo Mesalamine Product Portfolio
- 4.10.5 Corden Pharma Bergamo Recent Developments
- 4.11 CTX Lifescience
- 4.11.1 CTX Lifescience Company Information
- 4.11.2 CTX Lifescience Business Overview
- 4.11.3 CTX Lifescience Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 CTX Lifescience Mesalamine Product Portfolio
- 4.11.5 CTX Lifescience Recent Developments
- 4.12 Ishita Active Pharma Ingredients
- 4.12.1 Ishita Active Pharma Ingredients Company Information
- 4.12.2 Ishita Active Pharma Ingredients Business Overview
- 4.12.3 Ishita Active Pharma Ingredients Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Ishita Active Pharma Ingredients Mesalamine Product Portfolio
- 4.12.5 Ishita Active Pharma Ingredients Recent Developments
- 4.13 YC Biotech (Jiangsu)
- 4.13.1 YC Biotech (Jiangsu) Company Information
- 4.13.2 YC Biotech (Jiangsu) Business Overview
- 4.13.3 YC Biotech (Jiangsu) Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 YC Biotech (Jiangsu) Mesalamine Product Portfolio
- 4.13.5 YC Biotech (Jiangsu) Recent Developments
- 4.14 Xinxiang Tianfeng Fine Chemical
- 4.14.1 Xinxiang Tianfeng Fine Chemical Company Information
- 4.14.2 Xinxiang Tianfeng Fine Chemical Business Overview
- 4.14.3 Xinxiang Tianfeng Fine Chemical Mesalamine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Xinxiang Tianfeng Fine Chemical Mesalamine Product Portfolio
- 4.14.5 Xinxiang Tianfeng Fine Chemical Recent Developments
5 Global Mesalamine Market Scenario by Region
- 5.1 Global Mesalamine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mesalamine Sales by Region: 2021-2032
- 5.2.1 Global Mesalamine Sales by Region: 2021-2026
- 5.2.2 Global Mesalamine Sales by Region: 2027-2032
- 5.3 Global Mesalamine Revenue by Region: 2021-2032
- 5.3.1 Global Mesalamine Revenue by Region: 2021-2026
- 5.3.2 Global Mesalamine Revenue by Region: 2027-2032
- 5.4 North America Mesalamine Market Facts & Figures by Country
- 5.4.1 North America Mesalamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mesalamine Sales by Country (2021-2032)
- 5.4.3 North America Mesalamine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Mesalamine Market Facts & Figures by Country
- 5.5.1 Europe Mesalamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mesalamine Sales by Country (2021-2032)
- 5.5.3 Europe Mesalamine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Mesalamine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mesalamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mesalamine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mesalamine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mesalamine Market Facts & Figures by Country
- 5.7.1 South America Mesalamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mesalamine Sales by Country (2021-2032)
- 5.7.3 South America Mesalamine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Mesalamine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mesalamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mesalamine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mesalamine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Mesalamine Sales by Type (2021-2032)
- 6.1.1 Global Mesalamine Sales by Type (2021-2032) & (MT)
- 6.1.2 Global Mesalamine Sales Market Share by Type (2021-2032)
- 6.2 Global Mesalamine Revenue by Type (2021-2032)
- 6.2.1 Global Mesalamine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Mesalamine Revenue Market Share by Type (2021-2032)
- 6.3 Global Mesalamine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Mesalamine Sales by Application (2021-2032)
- 7.1.1 Global Mesalamine Sales by Application (2021-2032) & (MT)
- 7.1.2 Global Mesalamine Sales Market Share by Application (2021-2032)
- 7.2 Global Mesalamine Revenue by Application (2021-2032)
- 7.2.1 Global Mesalamine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mesalamine Revenue Market Share by Application (2021-2032)
- 7.3 Global Mesalamine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mesalamine Value Chain Analysis
- 8.1.1 Mesalamine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mesalamine Production Mode & Process
- 8.2 Mesalamine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mesalamine Distributors
- 8.2.3 Mesalamine Customers
9 Global Mesalamine Analyzing Market Dynamics
- 9.1 Mesalamine Industry Trends
- 9.2 Mesalamine Industry Drivers
- 9.3 Mesalamine Industry Opportunities and Challenges
- 9.4 Mesalamine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst